| Title |
NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease
|
|---|---|
| Published in |
Molecular Neurobiology, March 2017
|
| DOI | 10.1007/s12035-017-0467-9 |
| Pubmed ID | |
| Authors |
Jun Yin, Fanpeng Zhao, Jeremy E. Chojnacki, Jacob Fulp, William L. Klein, Shijun Zhang, Xiongwei Zhu |
| Abstract |
The activation of the NLRP3 inflammasome signaling pathway plays an important role in the neuroinflammation in Alzheimer's disease (AD). In this study, we investigated the effects of JC-124, a rationally designed NLRP3 inflammasome inhibitor, on AD-related deficits in CRND8 APP transgenic mice (TgCRND8). We first demonstrated increased formation and activation of NLRP3 inflammasome in TgCRND8 mice compared to non-transgenic littermate controls, which was inhibited by the treatment with JC-124. Importantly, JC-124 treatment led to decreased levels of Aβ deposition and decreased levels of soluble and insoluble Aβ1-42 in the brain of CRND8 mice which was accompanied by reduced β-cleavage of APP, reduced activation of microglia but enhanced astrocytosis. Oxidative stress was decreased and synaptophysin was increased in the CRND8 mice after JC-124 treatment, demonstrating a neuroprotective effect. Overall, these data demonstrated beneficial effects of JC-124 as a specific NLRP3 inflammasome inhibitor in AD mouse model and supported the further development of NLRP3 inflammasome inhibitors as a viable option for AD therapeutics. |
Mendeley readers
The data shown below were compiled from readership statistics for 152 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | <1% |
| Unknown | 151 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 27 | 18% |
| Student > Bachelor | 23 | 15% |
| Student > Master | 22 | 14% |
| Researcher | 18 | 12% |
| Professor > Associate Professor | 7 | 5% |
| Other | 22 | 14% |
| Unknown | 33 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 30 | 20% |
| Biochemistry, Genetics and Molecular Biology | 20 | 13% |
| Medicine and Dentistry | 16 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 10% |
| Agricultural and Biological Sciences | 13 | 9% |
| Other | 18 | 12% |
| Unknown | 40 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2017.
All research outputs
#4,209,783
of 22,958,253 outputs
Outputs from Molecular Neurobiology
#879
of 3,477 outputs
Outputs of similar age
#75,980
of 310,734 outputs
Outputs of similar age from Molecular Neurobiology
#17
of 73 outputs
Altmetric has tracked 22,958,253 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,477 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,734 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.